3 documents found, page 1 of 1
Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisati...
Antunes, Liliana; Rojas-Castro, Madelyn; Lozano, Marcos; Martínez-Baz, Iván; Leroux-Roels, Isabel; Borg, Maria-Louise; Oroszi, BeatrixWe estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (≥ 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days ...
Vaccine effectiveness against influenza A(H3N2) and B among laboratory‐confirme...
Rose, Angela M.C.; Kissling, Esther; Gherasim, Alin; Casado, Itziar; Bella, Antonino; Launay, Odile; Lazăr, Mihaela; Marbus, Sierk; Kuliese, MonikaBackground: Influenza A(H3N2), A(H1N1)pdm09 and B viruses co-circulated in Europe in 2017-18, predominated by influenza B. WHO-recommended, trivalent vaccine components were lineage-mismatched for B. The I-MOVE hospital network measured 2017-18 seasonal influenza vaccine effectiveness (IVE) against influenza A(H3N2) and B among hospitalised patients (≥65 years) in Europe. Methods: Following the same generic pro...
Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2)...
Rondy, Marc; Gherasim, Alin; Casado, Itziar; Launay, Odile; Rizzo, Caterina; Pitigoi, Daniela; Mickiene, Aukse; Marbus, Sierk D; Machado, AusendaIn a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could...